Tags · Compound
semaglutide
GLP-1 receptor agonist; the compound with the largest published human dataset in this class.
Related in this group: tirzepatide · retatrutide · cagrilintide · cagrisema · liraglutide · dulaglutide · exenatide · orforglipron · oral semaglutide · survodutide · mazdutide · amylin analogues
80 topics · page 3 of 3
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Second pass at: Semaglutide and alcohol: what is actually documented
Second pass at: Semaglutide and alcohol: what is actually documented Writing it up because I had to work it out twice and would rather nobody else did. I have seen STEP 1 ( N Engl J Med , 2021) cited in…
|
+15 | 19 | 4.4k | 13mo |
|
[2026 update] Dose numbers across compounds are not on the same scale
On the subject in the title: Dose numbers across compounds are not on the same scale Working notes rather than a conclusion. I have read the maintained page on this and I still have a gap, so I am asking…
|
+14 | 18 | 1.2k | 13mo |
|
Half-life, steady state, and accumulation worked through
Half-life, steady state, and accumulation worked through Writing it up because I had to work it out twice and would rather nobody else did. Working through the identity arithmetic and I would like it checked.…
|
+115 | 130 | 44k | 13mo |
|
Albumin binding and how it produces a long half-life
Albumin binding and how it produces a long half-life — setting out what I have, and where I think it stops being reliable. I would like to understand what this number means before I repeat it anywhere. A…
|
+38 | 44 | 6.6k | 14mo |
|
Reaching a dose and staying there for a year: a longitudinal note
Reaching a dose and staying there for a year: a longitudinal note Writing it up because I had to work it out twice and would rather nobody else did. I have read the maintained page on this and I still have a…
|
2 | 763 | 15mo | |
|
Why appetite effects are mostly central
Why appetite effects are mostly central I have a specific reason for asking rather than idle curiosity, and the context is below. Posting the method first, because I know what the first three replies will…
|
2 | 56k | 16mo | |
|
Biased agonism: a real phenomenon, an over-used explanation
Posting this under the heading it deserves: Biased agonism: a real phenomenon, an over-used explanation Everything below is what sits behind that. A documentation question rather than an analytical one. I…
|
+130 | 135 | 23k | 16mo |
|
Titrating on tolerability rather than on the calendar — the long version
Titrating on tolerability rather than on the calendar — the long version Writing it up because I had to work it out twice and would rather nobody else did. Reporting something rather than asking about it, in…
|
2 | 7.7k | 17mo | |
|
Second pass at: Albumin binding and how it produces a long half-life
Posting this under the heading it deserves: Second pass at: Albumin binding and how it produces a long half-life Everything below is what sits behind that. I would like to understand what this number means…
|
+7 | 11 | 31k | 17mo |
|
Semaglutide in people without diabetes: what the evidence base looks like
Semaglutide in people without diabetes: what the evidence base looks like Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SUSTAIN 6 ( N Engl J Med , 2016).…
|
+2 | 6 | 18k | 17mo |
|
Revisiting: Holding a dose indefinitely: is there a documented downside?
The question in the title: Revisiting: Holding a dose indefinitely: is there a documented downside? I will give what I have already checked below so nobody repeats it. A question about technique rather than…
|
+26 | 30 | 4.5k | 18mo |
|
Follow-up: Where the four-week escalation interval comes from, and what it is not
Where the four-week escalation interval comes from, and what it is not Writing it up because I had to work it out twice and would rather nobody else did. I have read the maintained page on this and I still…
|
+131 | 147 | 47k | 18mo |
|
Follow-up: Semaglutide versus liraglutide head to head: reading STEP 8 carefully
Semaglutide versus liraglutide head to head: reading STEP 8 carefully — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim…
|
+1 | 5 | 11k | 20mo |
|
Tracking semaglutide's approved indications across jurisdictions, dated — does this still hold?
Tracking semaglutide's approved indications across jurisdictions, dated — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing SCALE ( N…
|
+58 | 62 | 49k | 20mo |
|
Glucagon receptor agonism in a weight-loss compound
On the subject in the title: Glucagon receptor agonism in a weight-loss compound Working notes rather than a conclusion. Posting the method first, because I know what the first three replies will otherwise…
|
2 | 5.1k | 20mo | |
|
Time to steady state after a dose increase
On the subject in the title: Time to steady state after a dose increase Working notes rather than a conclusion. A documentation question rather than an analytical one. I have a certificate in front of me that…
|
+151 | 163 | 9.7k | 21mo |
|
The C-cell question: rodent findings and their human context — what changed since
The C-cell question: rodent findings and their human context — what changed since — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support…
|
+61 | 65 | 1.3k | 22mo |
|
The most common factual error about semaglutide on the internet
On the subject in the title: The most common factual error about semaglutide on the internet Working notes rather than a conclusion. Session topic: STEP 2 ( Lancet , 2021). Please read it before posting; the…
|
2 | 49k | 2y | |
|
Where the four-week escalation interval comes from, and what it is not
On the subject in the title: Where the four-week escalation interval comes from, and what it is not Working notes rather than a conclusion. I have read the maintained page on this and I still have a gap, so I…
|
+56 | 60 | 21k | 2y |
|
Splitting a weekly dose in two: the pharmacokinetic argument against — the long version
Posting this under the heading it deserves: Splitting a weekly dose in two: the pharmacokinetic argument against — the long version Everything below is what sits behind that. Reporting something rather than…
|
+138 | 148 | 1.8k | 2y |